{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:30:01Z","timestamp":1761514201476,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10096-018-3256-0","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T01:29:38Z","timestamp":1525397378000},"page":"1345-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005\u20132016)"],"prefix":"10.1007","volume":"37","author":[{"name":"the CARESS investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6046-1050","authenticated-orcid":false,"given":"Ian","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Paes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bjornson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"3256_CR1","unstructured":"Website: (\n                    http:\/\/www.cysticfibrosis.ca\/wp-content\/uploads\/2013\/10\/The-Facts-About-Cystic-Fibrosis.pdf\n                    \n                  . Accessed 6 July 2017)"},{"issue":"4","key":"3256_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10545-007-0690-z","volume":"30","author":"BL Therrell","year":"2007","unstructured":"Therrell BL, Adams J (2007) Newborn screening in North America. J Inherit Metab Dis 30(4):447\u2013465","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3256_CR3","first-page":"10","volume":"45","author":"CL Collins","year":"2002","unstructured":"Collins CL, Pollard AJ (2002) Respiratory syncytial virus infections in children and adults. J Inf Secur 45(1):10\u201317","journal-title":"J Inf Secur"},{"issue":"4","key":"3256_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","volume":"5","author":"J Figueras-Aloy","year":"2016","unstructured":"Figueras-Aloy J, Manzoni P, Paes B, Sim\u00f5es EA, Bont L, Checchia PA, Fauroux B, Carbonell-Estrany X (2016) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther 5(4):417\u2013452","journal-title":"Infect Dis Ther"},{"issue":"4","key":"3256_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40121-016-0137-7","volume":"5","author":"B Paes","year":"2016","unstructured":"Paes B, Fauroux B, Figueras-Aloy J, Bont L, Checchia PA, Sim\u00f5es EA, Manzoni P, Carbonell-Estrany X (2016) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther 5(4):453\u2013471","journal-title":"Infect Dis Ther"},{"issue":"1","key":"3256_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40121-016-0142-x","volume":"6","author":"PA Checchia","year":"2017","unstructured":"Checchia PA, Paes B, Bont L, Manzoni P, Sim\u00f5es EA, Fauroux B, Figueras-Aloy J, Carbonell-Estrany X (2017) Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease. Infect Dis Ther 6(1):37\u201356","journal-title":"Infect Dis Ther"},{"issue":"3","key":"3256_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40121-017-0160-3","volume":"6","author":"P Manzoni","year":"2017","unstructured":"Manzoni P, Figueras-Aloy J, Sim\u00f5es EAF, Checchia PA, Fauroux B, Bont L, Paes B, Carbonell-Estrany X (2017) Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther 6(3):383\u2013411","journal-title":"Infect Dis Ther"},{"issue":"10","key":"3256_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00006454-199910000-00006","volume":"18","author":"SR Arnold","year":"1999","unstructured":"Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18(10):866\u2013869","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"3256_CR9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0022-3476(88)80008-8","volume":"113","author":"SH Abman","year":"1988","unstructured":"Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113(5):826\u2013830","journal-title":"J Pediatr"},{"issue":"3","key":"3256_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1542\/peds.103.3.619","volume":"103","author":"PW Hiatt","year":"1999","unstructured":"Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103(3):619\u2013626","journal-title":"Pediatrics"},{"issue":"2","key":"3256_CR11","doi-asserted-by":"publisher","first-page":"e89186","DOI":"10.1371\/journal.pone.0089186","volume":"9","author":"J Murray","year":"2014","unstructured":"Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, Saxena S, Medicines for Neonates Investigator Group (2014) Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One 9(2):e89186","journal-title":"PLoS One"},{"issue":"6","key":"3256_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/cid\/cir928","volume":"54","author":"K Kristensen","year":"2012","unstructured":"Kristensen K, Hjuler T, Ravn H, Sim\u00f5es EA, Stensballe LG (2012) Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 54(6):810\u2013817","journal-title":"Clin Infect Dis"},{"issue":"6 Suppl","key":"3256_CR13","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","volume":"155","author":"D Borowitz","year":"2009","unstructured":"Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, Marshall BC, Accurso FJ (2009) Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 155(6 Suppl):S73\u2013S93","journal-title":"J Pediatr"},{"issue":"9","key":"3256_CR14","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","volume":"13","author":"B Resch","year":"2017","unstructured":"Resch B (2017) Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 13(9):2138\u20132149","journal-title":"Hum Vaccin Immunother"},{"key":"3256_CR15","doi-asserted-by":"crossref","unstructured":"The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 102(3 Pt 1):531\u2013537","DOI":"10.1542\/peds.102.3.531"},{"issue":"4","key":"3256_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, Cardiac Synagis Study Group (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532\u2013540","journal-title":"J Pediatr"},{"issue":"2","key":"3256_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1203\/PDR.0b013e318220a553","volume":"70","author":"TF Feltes","year":"2011","unstructured":"Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group (2011) A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 70(2):186\u2013191","journal-title":"Pediatr Res"},{"issue":"5","key":"3256_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ppul.22826","volume":"49","author":"M Gaboli","year":"2014","unstructured":"Gaboli M, de la Cruz \u00d2, de Ag\u00fcero MI, Moreno-Gald\u00f3 A, P\u00e9rez GP, de Querol MS (2014) Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol 49(5):490\u2013502","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"3256_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.aller.2013.09.003","volume":"43","author":"M S\u00e1nchez-Solis","year":"2015","unstructured":"S\u00e1nchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L (2015) Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis. Allergol Immunopathol (Madr) 43(3):298\u2013303","journal-title":"Allergol Immunopathol (Madr)"},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"917068","DOI":"10.1155\/2013\/917068","volume":"2013","author":"B Paes","year":"2013","unstructured":"Paes B, Mitchell I, Li A, Harimoto T, Lanct\u00f4t KL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol 2013:917068","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"3256_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/INF.0000000000001340","volume":"36","author":"P Manzoni","year":"2017","unstructured":"Manzoni P, Paes B, Lanct\u00f4t KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A (2017) Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study. Pediatr Infect Dis J 36(1):2\u20138","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"3256_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ppul.23376","volume":"51","author":"HE Groves","year":"2016","unstructured":"Groves HE, Jenkins L, Macfarlane M, Reid A, Lynn F, Shields MD (2016) Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. Pediatr Pulmonol 51(4):379\u2013385","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"3256_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/INF.0b013e31821146f7","volume":"30","author":"I Mitchell","year":"2011","unstructured":"Mitchell I, Paes BA, Li A, Lanct\u00f4t KL, CARESS investigators (2011) The Canadian registry of palivizumab. Pediatr Infect Dis J 30(8):651\u2013655","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"3256_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1936","volume":"37","author":"KP Kua","year":"2017","unstructured":"Kua KP, Lee SWH (2017) Systematic review of the safety and efficacy of palivizumab among infants and young children with cystic fibrosis. Pharmacotherapy 37(6):755\u2013769","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3256_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/pch\/20.6.321","volume":"20","author":"JL Robinson","year":"2015","unstructured":"Robinson JL, Le Saux N, Canadian Paediatric Society, Infectious Diseases and Immunization Committee (2015) Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 20(6):321\u2013333","journal-title":"Paediatr Child Health"},{"issue":"2","key":"3256_CR26","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1542\/peds.2014-1666","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134(2):e620\u2013e638","journal-title":"Pediatrics"},{"key":"3256_CR27","first-page":"CD007743","volume":"7","author":"KA Robinson","year":"2016","unstructured":"Robinson KA, Odelola OA, Saldanha IJ (2016) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 7:CD007743","journal-title":"Cochrane Database Syst Rev"},{"key":"3256_CR28","unstructured":"Cohen AH, Boron ML, Gaithersburg DC (2005) A phase IV study of the safety of Synagis (palivizumab) for the prophylaxis of respiratory disease in children with cystic fibrosis [Abstract]. International Meeting, SanDiego, California"},{"key":"3256_CR29","unstructured":"Website: (\n                    http:\/\/www.cysticfibrosis.ca\/our-programs\/advocacy\/cf-newborn-screening\n                    \n                  . Accessed 2 July 2017)"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-018-3256-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-018-3256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:14:47Z","timestamp":1556910887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-018-3256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1007\/s10096-018-3256-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"12 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AbbVie had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. A.L., B.P., I.M. and K.L. have received investigator-initiated research funding or received compensation as advisors or lecturers from AbbVie Corporation and MedImmune. S.W. has no conflicts of interest to declare. No honorarium, grant, or other form of payment was given to anyone to produce the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Obtained from appropriate Research Ethics review boards at all participating centers and at the coordinating center, Medical Outcomes and Research in Economics (MORE\u00ae) Research Group, Sunnybrook Health Sciences Centre, University of Toronto,","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in writing from parents or legal guardians of all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}